Cyprotex and InSphero have teamed up to provide a joint service offering that will give clients access to advanced cellular models of drug-induced liver toxicity. The new drug screening service, carried out at Cyprotex’ laboratories, will use InSpero’s 3D InSight™ liver model, which allows multiple dose studies to be performed over an extended time course.
CRO Cyprotex offers preclinical in vitro and in silico ADME/Tox services to drug discovery, pharma, and academic/nonprofit organizations worldwide. InSphero is a specialist in 3D microtissue research, and has developed a high-throughput technology for generating 3D microtissues from single cells. The firm claims its tissue models are scaffold-free and don’t rely on a bioartificial matrix for tissue formation, which means they are highly functional and demonstrate stable enzyme activity over longer periods of time than traditional microtissue constructs. In comparison with 2D cultures, the 3D microtissues thus more closely mimic native tissue and form natural cell-cell attachments. Both single cell type and multiple cell type models can be produced.
“Our joint offering combines leading 3D cell culture expertise with the proven ADME-Tox experience of a world-leading specialist,” comments Jan Lichtenberg, Ph.D., InSphero cofounder and CEO. “This assures high-quality data and reliable processes for our fee-for-service customers and makes advanced, predictive toxicology testing easily available to drug developers worldwide.”